

**Remarks**

Claims 12-13, 15-16 and 20-21 are present in the instant application. Claims 12-13, 15-16 and 20-21 have been amended and claims 1-11, 14, 17-19 and 22-35 have been canceled. No new matter has been added. Applicants have attached an abstract on a separate sheet of paper as required by US practice, and have amended the specification for purposes of adding the priority information.

Applicants respectfully submit that the presently claimed combination is patentable over the cited art, and request allowance of the present claims.

Respectfully submitted,



Virginia C. Bennett  
Attorney for Applicants  
Registration No. 37,092

Date: 8 Aug - 03  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709  
Telephone: (919)483-1012  
Facsimile: (919)483-7988